首页|期刊导航|新中医|芪冬颐心颗粒联合艾司西酞普兰治疗心脏神经官能症临床研究

芪冬颐心颗粒联合艾司西酞普兰治疗心脏神经官能症临床研究OA

Clinical Study on Qidong Yixin Granules Combined with Escitalopram in the Treatment of Cardiac Neurosis

中文摘要英文摘要

目的:观察芪冬颐心颗粒联合艾司西酞普兰治疗心脏神经官能症(CN)的临床疗效.方法:选取2024年1-12月舟山市普陀区人民医院收治的60例CN患者,按照双盲法分组原则,使用随机数字表、密封信封法将患者随机分为联合组和西药组各30例.2组均接受心理疏导及生活方式调整,西药组采用艾司西酞普兰片治疗,联合组在西药组基础上加用芪冬颐心颗粒治疗.2组疗程均为8周.观察比较2组临床疗效,治疗前后中医证候评分、心理状态评分[焦虑自评量表(SAS)、抑郁自评量表(SDS)]、24 h心率、24 h早搏次数、血清炎症因子[肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)]及安全性.结果:治疗后,总有效率联合组为93.33%(28/30),西药组为73.33%(22/30),组间比较,差异有统计学意义(P<0.05).治疗后,2组中医证候评分均较治疗前降低(P<0.05);且联合组评分低于西药组(P<0.05).治疗后,2组SAS评分、SDS评分均较治疗前降低(P<0.05),且联合组2项评分均低于西药组(P<0.05).治疗后,2组24 h心率、24 h早搏次数均较治疗前降低(P<0.05),且联合组24 h心率、24 h早搏次数均少于西药组(P<0.05).治疗后,2组TNF-α、hs-CRP水平均较治疗前降低(P<0.05),且联合组2项指标水平均低于西药组(P<0.05).治疗期间,联合组不良反应发生率为10.00%(3/30),西药组为33.33%(10/30),组间比较,差异有统计学意义(P<0.05).结论:芪冬颐心颗粒联合艾司西酞普兰片治疗CN疗效显著,可下调血清炎症因子水平,缓解患者抑郁、焦虑状态,且安全性良好.

Objective:To observe the clinical efficacy of Qidong Yixin Granules combined with Escitalopram in the treatment of cardiac neurosis(CN).Methods:A total of 60 patients with CN admitted to Putuo District People's Hospital of Zhoushan from January to December 2024 were selected.According to the double-blind grouping principle,the patients were randomly divided into the combination group and the western medicine group using the random number table method and sealed envelope method,with 30 cases in each group.Both groups received psychological counseling and lifestyle adjustments.The western medicine group was treated with Escitalopram Tablets,while the combination group received Qidong Yixin Granules in addition to the treatment given to the western medicine group.The course of treatment was eight weeks for both groups.The clinical efficacy,traditional Chinese medicine syndrome scores,psychological status scores[Self-Rating Anxiety Scale(SAS),Self-Rating Depression Scale(SDS)],24-hour heart rate,24-hour premature beat count,levels of serum inflammatory factors[tumor necrosis factor-alpha(TNF-α),high-sensitivity C-reactive protein(hs-CRP)]before and after treatment,and safety were observed and compared between the two groups.Results:After treatment,the total effective rate was 93.33%(28/30)in the combination group and 73.33%(22/30)in the western medicine group,with a statistically significant difference between the two groups(P<0.05).After treatment,the traditional Chinese medicine syndrome scores in both groups decreased compared with those before treatment(P<0.05);and the traditional Chinese medicine syndrome score in the combination group was lower than that in the western medicine group(P<0.05).After treatment,the SAS and SDS scores in both groups decreased compared with those before treatment(P<0.05),and the SAS and SDS scores in the combination group were lower than those in the western medicine group(P<0.05).After treatment,the 24-hour heart rate and 24-hour premature beat count in both groups decreased compared with those before treatment(P<0.05),and the 24-hour heart rate and 24-hour premature beat count in the combination group were lower than those in the western medicine group(P<0.05).After treatment,the levels of TNF-α and hs-CRP in both groups decreased compared with those before treatment(P<0.05),and the levels of TNF-α and hs-CRP in the combination group were lower than those in the western medicine group(P<0.05).During treatment,the incidence of adverse reactions was 10.00%(3/30)in the combination group and 33.33%(10/30)in the western medicine group,with a statistically significant difference between the two groups(P<0.05).Conclusion:The combination of Qidong Yixin Granules and Escitalopram Tablets has a significant therapeutic effect on CN,which can downregulate the levels of serum inflammatory factors,alleviate depression and anxiety of patients,and has good safety.

徐君;缪秋娜;赵蒙佳

舟山市普陀区人民医院神经内科,浙江 舟山 316100舟山市普陀区人民医院神经内科,浙江 舟山 316100舟山市普陀区人民医院神经内科,浙江 舟山 316100

医药卫生

心脏神经官能症艾司西酞普兰芪冬颐心颗粒焦虑自评量表抑郁自评量表炎症因子

Cardiac neurosisEscitalopramQidong Yixin GranulesSelf-Rating Anxiety ScaleSelf-Rating Depression ScaleInflammatory factors

《新中医》 2026 (12)

28-33,6

浙江省医学会临床医学专项资金项目(2024ZYC-A497)

10.13457/j.cnki.jncm.2026.12.005

评论